Earnings Forecast Research on Impax Laboratories, Inc. (IPXL)

Impax Laboratories, Inc. has received $0.16 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 8 Financial Advisor in the Stock Trading Firms. Among 8 Analysts, Bottom line EPS Estimate for the current quarter is $0.11 while the top line estimate is $0.2 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -74.19%.

Impax Laboratories, Inc. results fell short with a surprise EPS of -7.5% or $-0.03. The Actual EPS was $0.37 compared to the Estimated EPS of $0.4 during its most recent quarterly earnings.

Impax Laboratories, Inc. has a Price to Earnings ratio of 7.58 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 1.01. For the Most Recent Fiscal Year, Impax Laboratories, Inc. has a price to cash ratio of 5.03. For the Trailing twelve month period, company showed a Net Profit Margin of -19.93% and Return on Equity of the stock is 11.34%.

In the last quarter, Impax Laboratories, Inc. reported Annual Earnings of $0.37. Based on the filings, last years Annual Earnings was, $1.45. In the last Quarter, IPXL reported a surprise Earnings per Share of -7.5% . The consensus estimate for current quarter is $0.16 and for the current fiscal year, the estimate is $1.16. For the Next fiscal year, the estimate is $1.37 based on the consensus.

Impax Laboratories, Inc. (NASDAQ:IPXL) : On Tuesday heightened volatility was witnessed in Impax Laboratories, Inc. (NASDAQ:IPXL) which led to swings in the share price. The stock opened for trading at $12.3 and hit $13.3 on the upside , eventually ending the session at $13.15, with a gain of 6.48% or 0.8 points. The heightened volatility saw the trading volume jump to 1,446,464 shares. The 52-week high of the share price is $38.4299 and the company has a market cap of $971 million. The 52-week low of the share price is at $11.65 .

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas, namely Generic Pharmaceutical Products and Branded Pharmaceutical Products. In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. The company sells its products to large pharmaceutical wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies through strategic alliances and the companys global pharmaceuticals division.


Share this post

Leave a Reply